Medical Oncology

Uzm. Dr. Duygu Ercan Uzundal

Doctor and researcher Ankara Bilkent Şehir Hastanesi Ankara
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
  • Publications13 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-1277-8413ORCIDFrom source
  • Last synchronised7 November 2026 00:02https://ankarasehir.saglik.gov.tr/TR-331078/tibbi-onkoloji-klinigi-doktorlarimiz.html#duygu-ercan-uzundalsaglik.gov.tr

Scientific work

Publications

13 publications

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex

  2. Re: Three versus Six Cycles of Platinum-Based Chemotherapy Followed by Avelumab Maintenance as First-Line Treatment for Advanced Urothelial Cancer: The Phase II DISCUS Trial

    European Urology, 2026

    DOI 10.1016/j.eururo.2026.03.010 PMID 41925429 Source: OpenAlex

  3. Lenvatinib Dose Intensity and Tumor Response in Renal Cell Carcinoma Considering Tumor Burden and Nephrectomy Timing

    2026

    DOI 10.1093/jjco/hyag195 Source: ORCID

  4. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

    Turkish Journal of Gastroenterology, 2025

    DOI 10.5152/tjg.2025.24784 PMID 40241388 1 citation (Europe PMC) Open-access full textSource: ORCID

  5. Investigation of systemic treatment responses and prognostic factors in metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)

    Journal of Health Sciences and Medicine, 2025

    DOI 10.32322/jhsm.1744286 Open-access full textSource: ORCID

  6. 2914eP Association between quality of life and sleep disturbances, anxiety, depression, and fatigue during and after (neo)adjuvant taxane-based chemotherapy in breast cancer patients

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3526 Open-access full textSource: OpenAlex

  7. Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study

    Current Oncology, 2024

    DOI 10.3390/curroncol31110502 PMID 39590133 2 citations (Europe PMC) Open-access full textSource: ORCID

  8. 1492P The role of LACE index in predicting 30-day unplanned readmission in patients receiving immunotherapy

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1557 Open-access full textSource: ORCID

  9. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving Chemoimmunotherapy

    Expert Opinion on Pharmacotherapy, 2024

    DOI 10.1080/14656566.2024.2391007 PMID 39115275 4 citations (Europe PMC) Source: ORCID

  10. Quality and Reliability Analysis of Videos About Thulium Laser Enucleation of the Prostate on Youtube

    Urology, 2024

    DOI 10.1016/j.urology.2024.07.008 PMID 39002845 1 citation (Europe PMC) Source: ORCID

View all 13 publications